Novo Nordisk (NVO 1.18%) severed its partnership with Hims & Hers (HIMS 6.76%), arguing that the company breached the agreement between the two.
*Stock prices used were the afternoon prices of June 22, 2025. The video was published on June 24, 2025.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Hims & Hers Stock Is Crashing, and Is It a Buying Opportunity?
By Parkev Tatevosian, CFA
–
Jun 26, 2025 at 7:00AM
NYSE: HIMS
Hims & Hers Health
Market Cap
$11B
Today's Change
(6.76%) $3.13
Current Price
$49.41
Price as of June 27, 2025, 4:00 p.m. ET
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Stocks Mentioned
Hims & Hers Health
HIMS
$49.41
(6.76%)
$3.13
Novo Nordisk
NVO
$68.50
(1.18%)
$0.80
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
Massive News for Hims & Hers Stock Investors!
Down Over 30%, What's Going on With Hims & Hers stock?
Why Did Hims and Hers Stock Crash on Monday?
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.